EZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformation

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGANESH, Divya
dc.contributor.authorDAFAR, Amal
dc.contributor.authorNIKLASSON, Julia
dc.contributor.authorSANDBERG, Ingrid
dc.contributor.authorBRAZ-SILVA, Paulo
dc.contributor.authorSAPKOTA, Dipak
dc.contributor.authorOHMAN, Jenny
dc.contributor.authorGIGLIO, Daniel
dc.contributor.authorHASSEUS, Bengt
dc.date.accessioned2024-04-05T19:43:07Z
dc.date.available2024-04-05T19:43:07Z
dc.date.issued2023
dc.description.abstractBackground/Aim: The EZH2 complex is involved in cellular proliferation and modulates the immune response in cancer. Less is known about the importance of EZH2 in precancerous lesions such as oral leukoplakia (OL). The aim of the study was to explore the association between EZH2 expression, immune activation, and cancer transformation in OL. Patients and Methods: Analyses were retrospectively performed on nine OL cases that had undergone transformation to oral squamous cell carcinoma (OSCC; OL-ca) and nine that had not undergone transformation (OL-non). EZH2-expressing cells, CD3+ and CD8+ T cells, and CD1a+ Langerhans cells were visualized with immunohistofluorescence and counted. Results: A moderate positive correlation between CD3-and EZH2-expressing and CD8-and EZH2-expressing cells in the epithelium was found (r=0.57, p=0.01; r=0.59, p=0.01). The number of EZH2-expressing cells in the epithelium of OL-ca was significantly higher compared to OL-non (p=0.0002). Cancer - free survival rates differed significantly between patients with EZH2high compared to EZH2low expression (p=0.001). EZH2high expression in OL epithelium was associated with a 13-fold higher risk for developing OSCC (HR=12.8). Conclusion: EZH2 expression in oral epithelium predicts OSCC transformation of OL and correlates with the level of T-cell infiltration.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexScopus
dc.description.indexDimensions
dc.description.indexWoS
dc.description.sponsorshipHealthcare Board, Region Vaestra Goetaland, TUA Research Funding
dc.description.sponsorshipSahlgrenska Academy at the University of Gothenburg/Region Vaestra Goetaland
dc.description.sponsorshipAssar Gabrielsson Foundation
dc.description.sponsorshipAdlerbertska Foundation
dc.description.sponsorshipSwedish Dental Society
dc.description.sponsorshipGothenburg Dental Society
dc.description.sponsorshipKing Gustav V Jubilee Clinic Cancer Research Foundation, Goeteborg, Sweden
dc.description.sponsorshipRoyal Society of Arts and Sciences in Gothenburg, Sweden
dc.identifier.citationANTICANCER RESEARCH, v.43, n.4, p.1533-1542, 2023
dc.identifier.doi10.21873/anticanres.16302
dc.identifier.eissn1791-7530
dc.identifier.issn0250-7005
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/59260
dc.language.isoeng
dc.publisherINT INST ANTICANCER RESEARCHeng
dc.relation.ispartofAnticancer Research
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright INT INST ANTICANCER RESEARCHeng
dc.subjectOral potentially malignant disordereng
dc.subjectoral cancereng
dc.subjectpolycomb group proteinseng
dc.subjectimmune cellseng
dc.subjectbiomarkereng
dc.subject.otherdna methylation biomarkerseng
dc.subject.otherprogressioneng
dc.subject.othermechanismseng
dc.subject.otherdysplasiaeng
dc.subject.otherdiseaseeng
dc.subject.wosOncologyeng
dc.titleEZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformationeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countrySuécia
hcfmusp.affiliation.countryNoruega
hcfmusp.affiliation.countryÁrabia Saudita
hcfmusp.affiliation.countryisose
hcfmusp.affiliation.countryisosa
hcfmusp.affiliation.countryisono
hcfmusp.author.externalGANESH, Divya:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden
hcfmusp.author.externalDAFAR, Amal:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden; King Fahad Gen Hosp, Dept Oral & Maxillofacial Surg, Jeddah, Saudi Arabia
hcfmusp.author.externalNIKLASSON, Julia:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden
hcfmusp.author.externalSANDBERG, Ingrid:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden
hcfmusp.author.externalSAPKOTA, Dipak:Univ Oslo, Dept Oral Biol, Oslo, Norway
hcfmusp.author.externalOHMAN, Jenny:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Pathol, Gothenburg, Sweden
hcfmusp.author.externalGIGLIO, Daniel:Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Oncol, Gothenburg, Sweden
hcfmusp.author.externalHASSEUS, Bengt:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden; Publ Dent Hlth Serv, Clin Oral Med, Gothenburg, Vastra Gotaland, Sweden
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcPAULO HENRIQUE BRAZ DA SILVA
hcfmusp.description.beginpage1533
hcfmusp.description.endpage1542
hcfmusp.description.issue4
hcfmusp.description.volume43
hcfmusp.origemWOS
hcfmusp.origem.dimensionspub.1156568279
hcfmusp.origem.pubmed36974822
hcfmusp.origem.scopus2-s2.0-85150967195
hcfmusp.origem.wosWOS:000967840400002
hcfmusp.publisher.cityATHENSeng
hcfmusp.publisher.countryGREECEeng
hcfmusp.relation.referenceBalgkouranidou I, 2016, CLIN CHEM LAB MED, V54, P1385, DOI 10.1515/cclm-2015-0776eng
hcfmusp.relation.referenceBankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5eng
hcfmusp.relation.referenceCao W, 2011, CANCER PREV RES, V4, P1816, DOI 10.1158/1940-6207.CAPR-11-0130eng
hcfmusp.relation.referenceChen GB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00549eng
hcfmusp.relation.referenceChow A.Y., 2010, NATURE ED, V3, P7eng
hcfmusp.relation.referenceCiferri C, 2012, ELIFE, V1, DOI 10.7554/eLife.00005eng
hcfmusp.relation.referenceDong HP, 2019, CANCER RES, V79, P5587, DOI 10.1158/0008-5472.CAN-19-0428eng
hcfmusp.relation.referenceEsteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018eng
hcfmusp.relation.referenceGannot G, 2002, BRIT J CANCER, V86, P1444, DOI 10.1038/sj.bjc.6600282eng
hcfmusp.relation.referenceGao HX, 2016, INTERACT CARDIOV TH, V23, P681, DOI 10.1093/icvts/ivw198eng
hcfmusp.relation.referenceGibbings D, 2009, J LEUKOCYTE BIOL, V86, P251, DOI 10.1189/jlb.0109040eng
hcfmusp.relation.referenceGunawan M, NAT IMMUNOL, V16, P5eng
hcfmusp.relation.referenceHahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMRA021902eng
hcfmusp.relation.referenceHe S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02187-8eng
hcfmusp.relation.referenceHeichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935eng
hcfmusp.relation.referenceHu YL, 2009, CLIN CHEM LAB MED, V47, P923, DOI 10.1515/CCLM.2009.228eng
hcfmusp.relation.referenceHuang YJ, 2023, IMMUNOLOGY, V168, P30, DOI 10.1111/imm.13588eng
hcfmusp.relation.referenceJemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107, 10.3322/caac.21492]eng
hcfmusp.relation.referenceKaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307eng
hcfmusp.relation.referenceKang YN, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.658241eng
hcfmusp.relation.referenceLande R, 2010, ANN NY ACAD SCI, V1183, P89, DOI 10.1111/j.1749-6632.2009.05152.xeng
hcfmusp.relation.referenceLodish H, 2000, MOL CELL BIOLeng
hcfmusp.relation.referenceMargueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784eng
hcfmusp.relation.referenceMarkopoulou S, 2012, CLIN CHEM LAB MED, V50, P1723, DOI 10.1515/cclm-2012-0124eng
hcfmusp.relation.referenceMassano J, 2006, ORAL SURG ORAL MED O, V102, P67, DOI 10.1016/j.tripleo.2005.07.038eng
hcfmusp.relation.referenceMiller JS, 2019, ANNU REV CANC BIOL, V3, P77, DOI 10.1146/annurev-cancerbio-030518-055653eng
hcfmusp.relation.referenceÖhman J, 2012, SCAND J IMMUNOL, V76, P39, DOI 10.1111/j.1365-3083.2012.02701.xeng
hcfmusp.relation.referenceÖhman J, 2015, ANTICANCER RES, V35, P311eng
hcfmusp.relation.referenceParreno V, 2022, CELL RES, V32, P231, DOI 10.1038/s41422-021-00606-6eng
hcfmusp.relation.referencePasini D, 2016, CURR OPIN GENET DEV, V36, P50, DOI 10.1016/j.gde.2016.03.013eng
hcfmusp.relation.referencePietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004eng
hcfmusp.relation.referencePinto AC, 2020, OR SURG OR MED OR PA, V129, P600, DOI 10.1016/j.oooo.2020.02.017eng
hcfmusp.relation.referenceRuss BE, 2014, IMMUNITY, V41, P853, DOI 10.1016/j.immuni.2014.11.001eng
hcfmusp.relation.referenceShao FF, 2021, J LEUKOCYTE BIOL, V110, P77, DOI 10.1002/JLB.1RU0520-311Reng
hcfmusp.relation.referenceSperandio M, 2023, J ORAL PATHOL MED, V52, P418, DOI 10.1111/jop.13365eng
hcfmusp.relation.referenceToraño EG, 2012, CLIN CHEM LAB MED, V50, P1733, DOI 10.1515/cclm-2011-0902eng
hcfmusp.relation.referenceTumes DJ, 2013, IMMUNITY, V39, P819, DOI 10.1016/j.immuni.2013.09.012eng
hcfmusp.relation.referenceVrtacnik P, 2014, CLIN CHEM LAB MED, V52, P589, DOI 10.1515/cclm-2013-0770eng
hcfmusp.relation.referenceWarnakulasuriya S, 2020, ORAL ONCOL, V102, DOI 10.1016/j.oraloncology.2019.104550eng
hcfmusp.relation.referenceXu SB, 2023, ORAL DIS, V29, P3268, DOI 10.1111/odi.14332eng
hcfmusp.relation.referenceZhang SZ, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19020875eng
hcfmusp.relation.referenceZhang XL, 2018, J EXP MED, V215, P1365, DOI 10.1084/jem.20171417eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication1ace6a73-b9d8-41e6-85ff-dc13f394901a
relation.isAuthorOfPublication.latestForDiscovery1ace6a73-b9d8-41e6-85ff-dc13f394901a
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - LIM/52